The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Clomiphene citrate exposure was associated with higher rates of multiple births and perinatal adverse outcomes such as stillbirth.